CASP3 and neoplasm: Treatment with triptolide and the caspase inhibitor Z-VAD-FMK or the caspase-3 inhibitor Z-DEV-FMK only weakens the lethality of triptolide to tumor cells but does not completely eliminate the lethality of triptolide [35].